Show simple item record

Requirement for expert histopathological assessment of ovarian cancer and borderline tumors.

dc.contributor.authorSengupta, P S
dc.contributor.authorShanks, Jonathan H
dc.contributor.authorBuckley, C H
dc.contributor.authorRyder, W David J
dc.contributor.authorDavies, Julie
dc.contributor.authorReynolds, K
dc.contributor.authorSlade, Richard J
dc.contributor.authorKitchener, Henry C
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2009-11-23T10:18:43Z
dc.date.available2009-11-23T10:18:43Z
dc.date.issued2000-02
dc.identifier.citationRequirement for expert histopathological assessment of ovarian cancer and borderline tumors. 2000, 82 (4):760-2 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid10732741
dc.identifier.doi10.1054/bjoc.1999.0994
dc.identifier.urihttp://hdl.handle.net/10541/86649
dc.description.abstractThe distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subjectOvarian Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshCell Differentiation
dc.subject.meshDisease Progression
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshOvarian Neoplasms
dc.subject.meshRecurrence
dc.titleRequirement for expert histopathological assessment of ovarian cancer and borderline tumors.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital National Health Trust, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren
refterms.dateFOA2020-04-21T14:43:06Z
html.description.abstractThe distinction between borderline ovarian tumours (BOT) and ovarian carcinoma is made by histopathological assessment. Of 64 patients managed according to institutional BOT protocols, 27 (42%) had been referred with a diagnosis of ovarian carcinoma that was subsequently changed to BOT following histopathological review. The 70% 6-year event-free survival of the patients with a revised diagnosis was not significantly different from those who were referred with a diagnosis of BOT. This change in diagnosis is important as it avoids the need for chemotherapy for most patients and results in patients receiving appropriate information concerning prognosis. Interestingly, 24 patients (38.1%) reported a family history of epithelial cancer, a finding that has not been reported previously. Campaign


Files in this item

Thumbnail
Name:
91421.pdf
Size:
38.23Kb
Format:
PDF
Description:
From UNPAYWALL
Download

This item appears in the following Collection(s)

Show simple item record